Bafetinib enhances anti-tumor immunity by activating the NLRP3 inflammasome in macrophage - PubMed
8 hours ago
- #NLRP3 inflammasome
- #bafetinib
- #tumor immunotherapy
- Bafetinib, a clinical phase II drug, activates the NLRP3 inflammasome to enhance anti-tumor immunity.
- It targets the potassium channel KCNK6/TWIK2, blocking its degradation via chaperone-mediated autophagy to promote potassium efflux and inflammasome activation.
- A hypoxia-responsive nanoparticle (Baf@NPs) delivers bafetinib to tumors, releasing it specifically in the tumor microenvironment.
- Baf@NPs treatment significantly inhibits tumor growth and boosts anti-tumor immunity by activating the NLRP3 inflammasome in macrophages.
- Combining Baf@NPs with PD-1 antibodies further enhances anti-tumor immunity and improves tumor treatment outcomes.